Why Most AI Startups Fail in Healthcare With: Dr. Bernardo Perez-Villa and Dr. Peter Alperin
Why do so many AI startups fail in healthcare despite strong funding and promising innovation? In this interview, Dr. Bernardo Perez-Villa and Dr. Peter Alperin break down the structural, financial, and operational realities that determine whether digital health solutions succeed or fail. While AI offers unprecedented potential to augment clinical decision-making, real-world adoption depends less on technical performance and more on workflow integration, reimbursement strategy, and stakeholder alignment.
The discussion highlights a critical disconnect between clinical research success and practical implementation, emphasizing that healthcare systems are inherently risk-averse and resistant to disruption. From regulatory hurdles and CPT reimbursement challenges to product-market fit and go-to-market strategy, the conversation provides a clear-eyed view of what it takes to build viable healthcare AI solutions. For healthcare leaders, innovators, and investors, this interview offers actionable insights into navigating the complex healthcare innovation landscape.
Episode Contents:
About the Guest
Dr. Bernardo Perez-Villa is a cardiologist and healthcare innovation leader with experience across global health systems and digital health startups. He currently serves as a Research Supervisor at Cleveland Clinic Florida and has held leadership roles in health technology and commercialization. Connect with him on LinkedIn: https://www.linkedin.com/in/bperezvilla/
Dr. Peter Alperin is an internal medicine physician and digital health executive with leadership experience at Doximity and Archimedes. He is also a startup advisor and early-stage investor focused on healthcare innovation. Connect with him on LinkedIn: https://www.linkedin.com/in/peteralperin/
Key Takeaways
- Reimbursement strategy determines success more than clinical performance
- Product-market fit must align with real workflows, not just research results
- Start small, prove value, then scale with a focused go-to-market strategy
Transcript Summary
Why do most AI startups fail in healthcare?
AI startups often fail because they focus on innovation without addressing reimbursement, workflow integration, and stakeholder incentives. A strong product alone is not enough if no one pays for or adopts it.
Why is there a gap between clinical research and real-world adoption?
Clinical studies are conducted in controlled environments with aligned stakeholders and resources. In real-world healthcare systems, competing priorities, limited budgets, and workflow complexity reduce adoption.
What role does reimbursement play in success?
Reimbursement is critical. Without a viable payment model, even clinically valuable tools fail. Many startups underestimate the cost and complexity of securing CPT codes or sustainable revenue streams.
What are common red flags when evaluating AI startups?
Red flags include underestimating regulatory timelines, unclear reimbursement pathways, and lack of understanding of real clinical workflows. Overconfidence in FDA timelines is especially concerning.
What makes a healthcare AI startup viable?
Successful startups demonstrate strong founder expertise, clear product-market fit, and a focused go-to-market strategy. They prioritize solving a specific problem and scaling gradually.
Why is go-to-market strategy so important?
Even strong products fail without a clear path to adoption. Startups must define who pays, who uses the product, and how it integrates into existing systems.
What is overhyped about AI in healthcare?
AI replacing physicians is overhyped. Instead, AI will augment clinical workflows. Additionally, AI alone cannot fix systemic healthcare challenges without addressing incentives and processes.
What changes are needed to improve innovation in healthcare?
Simplifying evaluation processes, reducing regulatory friction, and enabling easier pilot testing would accelerate innovation while maintaining safety and rigor.
More Topics
- AI in Patient Care
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
Keep Exploring
About the Series
Leading oncology AI thought leaders Drs. Sanjay Juneja, Debra Patt, and Doug Flora bring you conversations at the intersection of medicine, data, and innovation. Each episode explores both the big picture and the breaking news in artificial intelligence and healthcare—examining how today’s technology is reshaping the practice and business of oncology.
From industry disruptors to clinical pioneers, guests share insights that bridge the gap between algorithms and the art of patient care.
To learn more about the mission and upcoming initiatives, visit tensorblack.ai and subscribe to stay ahead of the curve.